safety of glp-1 receptor agonists Frontiers GLP-1 Receptor Agonists for the
Description
The images or other third party material in this article are included in the articles Creative Commons licence, unless indicated otherwise in a credit line to the material
(2017) 312:E224E33
doi: 10.2337/db18-0729 [DOI] [PMC free article] [PubMed] [Google Scholar] 3.Mller TD, Finan B, Bloom SR, et al
, Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo
